Published: August 21, 2018

Introduction {#sec1}
============

The strict segregation of embryonic and extra-embryonic tissues constitutes the earliest cell fate decision in the pre-implantation mammalian embryo. Later, during gastrulation through coordinated patterning by Nodal and Bmp signaling, pluripotent epiblast cells are induced to form the three primary germ layers: mesoderm, definitive endoderm (DE), and ectoderm ([@bib48]). However, studies demonstrate that epiblast cells acquire competence to differentiate in response to inductive signaling cues at earlier stages ([@bib56]). This cellular transition, designated as lineage priming or epiblast maturation and characterized in cultured epiblast-like cells (EpiLCs) ([@bib7], [@bib23]), is associated with genome-wide reorganization of active enhancers, resulting in decreased expression of naive pluripotency genes, activation of primed and early differentiation genes, and importantly, stable repression of extra-embryonic gene expression ([@bib40], [@bib44]). However, relatively little is known about the underlying molecular mechanisms driving these cellular events.

Our early work showed that Nodal, a member of the transforming growth factor β (TGF-β) superfamily of secreted growth factors, is required for axis patterning in the early post-implantation stage embryo ([@bib6]). Loss-of-function embryos arrest before gastrulation, fail to form mesoderm, prematurely lose expression of pluripotency markers, and precociously activate neuroectoderm markers ([@bib6], [@bib9], [@bib39]). Nodal receptors activate the closely related downstream intracellular effectors Smad2 and Smad3 (Smad2/3) that translocate into the nucleus to regulate target gene expression ([@bib36]). Smad2/3 share \>90% amino acid identity and display partially overlapping expression patterns in the early embryo ([@bib14], [@bib62]). However, loss-of-function mutants display strikingly different phenotypes. Animals lacking Smad3 are adult viable ([@bib12]). In contrast, *Smad2* mutant embryos fail to acquire anterior-posterior patterning and arrest shortly after implantation ([@bib62]). Instead, because of loss of Smad2 in the extra-embryonic primitive endoderm (where Smad3 is not expressed), the epiblast defaults exclusively to an extra-embryonic mesodermal fate ([@bib14], [@bib62]). *Smad3* expression from the *Smad2* locus can rescue the lethal phenotype ([@bib15]). Moreover, Smad2/3 clearly function in a dose-dependent manner ([@bib61]). Thus, double-mutant embryos lacking both Smad2/3 abruptly arrest shortly after implantation and are severely disorganized ([@bib14]).

Previous efforts aimed at dissecting partially overlapping Smad2/3 functional contributions have been hampered by this early lethality. Here we exploited embryonic stem cells (ESCs) lacking both Smad2/3, in combination with directed *in vitro* differentiation protocols, to gain insight into the underlying defects. We observe that Smad2/3 double-mutant ESCs fail to undergo lineage priming or correct cell fate allocation and ectopically activate extra-embryonic genes. This priming defect was associated with inappropriate activation of Oct4-bound distal regulatory sites and enhanced Bmp target gene expression. Collectively, the present results demonstrate that combinatorial Smad2/3 activities are required to maintain embryonic identity in the early epiblast during lineage priming.

Results {#sec2}
=======

Smad2/3 Inactivation in ESCs Fails to Disrupt Self-Renewal and Expression of Pluripotency Marker Genes {#sec2.1}
------------------------------------------------------------------------------------------------------

To investigate functional contributions made by the closely related Smad2/3 transcriptional regulators, we targeted the *Smad3* promoter in *Smad2*^−/−^ (Smad2 knockout \[KO\]) ([@bib60]) or wild-type (WT) ESCs to generate *Smad2*^−/−^*;Smad3*^−/−^ ESCs (Smad2/3 double knockout \[DKO\]) and *Smad3*^−/−^ ESCs (Smad3 KO) ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Correctly targeted clones were identified by Southern blot analysis, and loss of Smad3 protein expression was confirmed by western blotting ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). WT, Smad2 KO, Smad3 KO, and Smad2/3 DKO ESCs cultured under 2i + LIF (2iL) or serum + LIF (SL) conditions were morphologically indistinguishable ([Figure S1](#mmc1){ref-type="supplementary-material"}D). Smad2/3 DKO ESCs efficiently formed colonies and displayed robust Oct4 and Nanog expression levels ([Figures 1](#fig1){ref-type="fig"}A, [S1](#mmc1){ref-type="supplementary-material"}D, and S1E).Figure 1Smad2/3 Repress Expression of Extra-Embryonic and Naive Pluripotency Genes during Lineage Priming(A) WT, Smad2 KO, Smad3 KO, or Smad2/3 DKO ESCs (2iL) were stained for Oct4 and Nanog and counterstained with DAPI.(B) Venn diagrams showing significant changes in gene expression shared by Smad2 KO, Smad3 KO, and Smad2/3 DKO ESCs, relative to WT ESCs, as determined by microarray profiling (n = 3 or 4). Genes uniquely differentially expressed by Smad2 KO or Smad3 KO ESCs were excluded from this analysis. A summary of deregulated genes is presented in [Table S1](#mmc2){ref-type="supplementary-material"}.(C) Pie charts of alkaline phosphatase (AP)-stained WT, Smad2 KO, Smad3 KO, or Smad2/3 DKO ESCs cultured for 5 days in the presence or absence of LIF (n = 3), corresponding to pluripotent, differentiated, or mixed colonies. See also [Figure S1](#mmc1){ref-type="supplementary-material"}F.(D) Scatterplot showing significantly (p \< 0.05, Benjamini-Hochberg adjusted) differentially expressed genes in Smad2/3 DKO EpiLCs compared to WT by RNA-seq (n = 3). The cutoff was set to \>1.5-fold change. Differentially expressed genes near Smad2/3 ChIP-seq peaks in day 3 EBs (≤50 kb of its transcriptional start site \[TSS\]) are indicated in yellow. The pie chart indicates the proportion of differentially expressed genes also showing Smad2/3 ChIP-seq peaks (≤50 kb of TSS).(E) Heatmap showing relative expression levels of pluripotency marker genes in Smad2/3 DKO ESCs, EpiLCs, and day 3 EBs compared to WT controls (n = 3 or 4). Profiles of Smad2 KO and Smad3 KO day 3 EBs are shown on the right.

To examine gene expression changes, we carried out transcriptional profiling experiments using microarrays. We identified 422 genes with significantly changed expression levels (209 down and 213 up) in Smad2/3 DKO ESCs cultured under SL conditions compared to WT ESCs ([Figure 1](#fig1){ref-type="fig"}B; [Table S1](#mmc2){ref-type="supplementary-material"}). Several Nodal targets (*Lefty1/2* and *Pitx2*) were downregulated, while Bmp target genes (*Id1*/2/*3)* were upregulated. Genes normally confined to trophectoderm derivatives (*Tle3*, *Plac1*, *Pparg*, and *Prl2c3*) and extra-embryonic primitive endoderm (*Pdgfra* and *Sox7*) were upregulated in Smad2/3 DKO ESCs. A subset of differentially expressed genes was also significantly altered in either Smad2 KO or Smad3 KO ESCs (33% and 12%, respectively) ([Figure 1](#fig1){ref-type="fig"}B). Smad2, but not Smad3, KO ESCs display upregulated extra-embryonic gene expression. There was no evidence for altered expression of pluripotency markers ([Table S1](#mmc2){ref-type="supplementary-material"}).

Loss of Smad2/3 Results in Activation of Extra-Embryonic and Bmp Target Gene Expression upon Exit from the Undifferentiated State {#sec2.2}
---------------------------------------------------------------------------------------------------------------------------------

To test whether these transcriptional changes potentially influence exit from the naive state, we induced differentiation by plating ESCs (SL) at low density in the absence of LIF and performed alkaline phosphatase (AP) staining to identify naive ESCs. Similar to WT or single-KO ESCs, Smad2/3 DKO ESCs gave rise to AP-negative colonies ([Figure 1](#fig1){ref-type="fig"}C). As for BMP4-treated WT ESCs that similarly exhibit a bias toward extra-embryonic gene expression, Smad2/3 DKO and to a lesser extent Smad2 KO ESC colonies displayed a distinctive, more flattened, epithelial morphology ([@bib22]) ([Figure S1](#mmc1){ref-type="supplementary-material"}F).

To further explore exit from the naive state, we compared gene expression profiles of WT and Smad2/3 DKO EpiLCs using RNA sequencing (RNA-seq). As expected, WT ESCs (2iL) induced to form EpiLCs by activin A and Fgf2 treatment adopted a flattened cell morphology. The appearance of Smad2/3 DKO EpiLCs closely resembled WT ([Figure S1](#mmc1){ref-type="supplementary-material"}G). RNA-seq analysis identified 2,098 genes with significantly changed expression in Smad2/3 DKO compared to WT EpiLCs (1,100 down and 998 up) ([Figure 1](#fig1){ref-type="fig"}D; [Table S2](#mmc3){ref-type="supplementary-material"}). We found that expression levels of Nodal-dependent genes (e.g., *Lefty1*/*2* and *Pitx2*) and early mesoderm markers (e.g., *T* and *Fgf8*) were downregulated in Smad2/3 DKO EpiLCs. However, Bmp targets (e.g., *Id1*/2/3/4) and extra-embryonic ectoderm (e.g., *Fgfr2* and *Tfap2c*), trophectoderm (e.g., *Gata2* and *Gata3*), and visceral endoderm (VE) (e.g., *H19* and *Sparc*) marker genes were activated.

Next, we compared the list of differentially expressed genes with published Smad2/3 chromatin immunoprecipitation sequencing (ChIP-seq) datasets ([@bib63]). We found that 18% of differentially expressed genes in Smad2/3 DKO EpiLCs were occupied by Smad2/3 in differentiated embryoid bodies (EBs), in contrast to only 3% in ESCs ([Table S2](#mmc3){ref-type="supplementary-material"}). Smad2/3-occupied differentially expressed genes included both Nodal and Bmp targets. Except for *Fgfr2* and *Tfap2c* (encoding Ap2γ) none of the ectopically activated extra-embryonic genes were found to be Smad2/3 occupied, which implicates an indirect regulatory mechanism, assuming Smad2/3 occupancy is similar between EpiLCs and EBs.

Combinatorial Smad2/3 Activities Control Pluripotency-Associated Gene Expression during Lineage Priming {#sec2.3}
-------------------------------------------------------------------------------------------------------

Smad2/3 DKO EpiLCs display enhanced expression of naive pluripotency markers (e.g., *Klf2* and *Rex1*) characteristic of the blastocyst inner cell mass, together with decreased expression of primed pluripotency markers (e.g., *Fgf5* and *Oct6*) ([Figure 1](#fig1){ref-type="fig"}E). Reduced Oct6 expression was confirmed by immunofluorescence staining experiments ([Figure S1](#mmc1){ref-type="supplementary-material"}G). In contrast, expression of the epiblast marker *Otx2* was unchanged ([Figures 1](#fig1){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}G). To further examine gene expression changes during differentiation, Smad2/3 DKO ESCs were induced to form EBs and transcriptional profiles were analyzed using microarrays. As shown in [Figure 1](#fig1){ref-type="fig"}E, Smad2/3 DKO EBs display striking downregulation of primed pluripotency markers and upregulated expression of naive pluripotency genes. In addition, when we analyzed single-KO EBs, we found that Smad2 KO EBs, but not Smad3 KO EBs, resembled Smad2/3 DKO EBs. Consistent with this, EpiLCs express *Smad2* at roughly 5-fold higher levels in comparison with *Smad3*. Thus, Smad2 activity is predominantly responsible for governing the gain of primed and/or differentiated identity during lineage priming.

Smad2/3 Influence Chromatin Accessibility during the ESC-to-EpiLC Transition {#sec2.4}
----------------------------------------------------------------------------

The preceding results demonstrate that Smad2/3 activities regulate pluripotency-associated gene expression. However, we detected a relatively low degree of overlap between Smad2/3-dependent transcripts and nearby sites of Smad2/3 binding using published Smad2/3 ChIP-seq datasets from day 3 EBs ([@bib63]). These experimental approaches provided only a limited view of the Smad2/3 regulatory network. Global changes in the activities of distal regulatory elements, such as enhancers, during acquisition of the primed state have been previously documented ([@bib7], [@bib17]). Therefore, we decided to evaluate possible changes affecting the distal regulatory element landscape in Smad2/3 DKO EpiLCs using the assay for transposase accessible chromatin (ATAC)-seq.

We identified 4,274 regulatory elements that were differentially accessible in Smad2/3 DKO compared to WT EpiLCs (3,234 decreased and 1,040 increased) ([Figure 2](#fig2){ref-type="fig"}A; [Table S3](#mmc4){ref-type="supplementary-material"}). To explore the possibility that Smad2/3-dependent regulatory elements potentially influence the transition to the primed state, we identified sites where chromatin accessibility is changed during the ESC-to-EpiLC transition by comparing EpiLC ATAC-seq data with our published WT ESC ATAC-seq dataset ([@bib55]). Most (90%) Smad2/3-dependent sites undergo changes in chromatin accessibility during the ESC-to-EpiLC transition ([Figure 2](#fig2){ref-type="fig"}B). Furthermore, many of these were located more than 5 kb from transcriptional start sites ([Figure 2](#fig2){ref-type="fig"}C) and displayed an enrichment for markers of distal regulatory elements, including p300, H3K27ac, and H3K4me1 ([Figure 2](#fig2){ref-type="fig"}D). These observations suggest that combinatorial Smad2/3 activities influence the global reconfiguration of the chromatin landscape during lineage priming.Figure 2Smad2/3 Influences the Activity of Oct4-Occupied Distal Regulatory Enhancers during Priming(A) Heatmap of regulatory elements with differential chromatin accessibility in Smad2/3 DKO EpiLCs compared to WT EpiLCs, as measured by ATAC-seq (false discovery rate \[FDR\] \< 0.05, fold change \> 1.5). Sites with decreased chromatin accessibility (top) and sites with increased chromatin accessibility (bottom) are ranked by decreasing and increasing ATAC signal change. See also [Table S3](#mmc4){ref-type="supplementary-material"}.(B and C) Pie charts indicating (B) distributions of differential accessible sites in Smad2/3 DKO EpiLCs compared to WT overlapping with regulatory elements gained or lost during the ESC-to-EpiLC transition or (C) the distance to known TSS as defined by Genomic Regions Enrichment of Annotations Tool (GREAT).(D) Heatmap read density plots of p300, H3K27ac, and H3K4me1 ChIP-seq signal at regulatory elements with differential accessibility in Smad2/3 DKO EpiLCs (ranked as in A).(E) Heatmap depicting the log2 fold change (log2FC) in gene expression in Smad2/3 DKO EpiLCs relative to WT EpiLCs as determined by RNA-seq. Genes nearest regulatory elements with differential accessibility in Smad2/3 DKO EpiLCs are shown.(F) Genome browser snapshots of RNA-seq and ATAC-seq tracks in Smad2/3 DKO and WT EpiLCs at selected genomic loci. ATAC-seq of WT ESCs, ChIP-seq tracks of Smad2/3 occupancy in ESCs and day 3 EBs, and Oct4 and Otx2 occupancy in EpiLCs are also shown.(G) Heatmap read density plots of WT Smad2/3, Smad1, Oct4, and Otx2 ChIP-seq signal in the indicated cell types at regulatory elements with differential accessibility in Smad2/3 DKO EpiLCs (ranked as in A). ESCs were treated with 10 ng/mL BMP4 for Smad1 ChIP-seq.(H) Motif enrichment analysis of regulatory elements with differential chromatin accessibility in Smad2/3 DKO EpiLCs. Motifs for transcription factors associated with primed or naive, extra-embryonic, and neural cell states were significantly enriched.

Changes in chromatin accessibility at distal regulatory elements in Smad2/3 DKO EpiLCs potentially influence expression of nearby genes. To test this possibility, we compared ATAC-seq and transcriptional profiles. We found that sites with decreased accessibility were associated with reduced expression of nearby genes ([Figure 2](#fig2){ref-type="fig"}E). For example, *Lefty1*/*2* and *Pitx2* display decreased chromatin accessibility at nearby enhancer regions normally occupied by Smad2/3 during differentiation ([Figures 2](#fig2){ref-type="fig"}F, 2G, and [S2](#mmc1){ref-type="supplementary-material"}A). In contrast, sites that displayed increased chromatin accessibility were associated with increased expression levels ([Figure 2](#fig2){ref-type="fig"}E); however, unlike sites showing decreased accessibility, these loci tended to have lower levels of Smad2/3 binding ([Figure 2](#fig2){ref-type="fig"}G). Sites of increased accessibility are associated with increased Smad1 occupancy in BMP4-treated ESCs ([@bib41]) ([Figure 2](#fig2){ref-type="fig"}G). Collectively, these results demonstrate that Smad2/3 act to promote full access to distal regulatory elements governing gene expression changes necessary for cells to transition to the primed state.

Oct4 and Otx2 Occupy Smad2/3-Dependent Distal Regulatory Elements {#sec2.5}
-----------------------------------------------------------------

Studies demonstrate that Oct4 binding switches from naive enhancers to primed enhancers at pluripotency genes coincident with occupancy by so-called mediators of the primed state, such as Otx2, during the ESC-to-EpiLC transition ([@bib7]). Here we observe in EpiLCs an enrichment of Oct4 and Otx2 ChIP-seq signals at Smad2/3-dependent sites that display decreased chromatin accessibility ([Figures 2](#fig2){ref-type="fig"}F and 2G). Motif enrichment analysis confirmed these sites are highly enriched for Oct4 and Otx2 binding motifs and those recognized by other priming factors, e.g., Oct6 and Foxd3 ([Figure 2](#fig2){ref-type="fig"}H). *Fgf5*, *Oct6*, and *Foxa2*, genes characteristic of the primed state, display decreased accessibility ([Figures 2](#fig2){ref-type="fig"}F and [S2](#mmc1){ref-type="supplementary-material"}B). In contrast, in the absence of Smad2/3, *Klf2*, an Oct4/Otx2-occupied gene that characterizes the naive state, shows increased accessibility at a neighboring distal regulatory element and increased expression levels ([Figure 2](#fig2){ref-type="fig"}F). These genomic regions were also enriched for naive, extra-embryonic, and neural transcription factor binding motifs ([Figure 2](#fig2){ref-type="fig"}H). However, accessibility near early differentiation and extra-embryonic marker genes appeared to be largely unaffected ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D). These observations strengthen the argument that cooperative binding by different transcription factors is required during lineage priming and demonstrate that Smad2/3, together with the pioneer factor Oct4 ([@bib43], [@bib51]), targets distal regulatory elements controlling the transition from the naive to the primed state.

Loss of Smad2/3 Disrupts Cell Fate Allocation during ESC Differentiation {#sec2.6}
------------------------------------------------------------------------

To investigate downstream consequences resulting from this priming defect, we re-examined the Smad2/3 DKO EB microarray profiles. We identified 3,104 genes showing significantly changed expression levels in Smad2/3 DKO compared to WT day 3 EBs (1,487 down and 1,617 up) ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Expression of the top 20 genes normally activated during differentiation was dramatically reduced in Smad2/3 DKO EBs ([Figure 3](#fig3){ref-type="fig"}A). Expression of several mesodermal (*Wnt3*, *T*, *Fgf8*, *Mixl1*, *Sp8*, *Eomes*, *Mesp1*, and *Lhx1*) and DE lineage marker genes (*Foxa2*, *Sox17*, *Cxcr4*, and *Gata6*), including a subset known to be direct targets of Smad2/3 in EBs ([@bib63]), were significantly downregulated ([Table S1](#mmc2){ref-type="supplementary-material"}). Profiling at an earlier point revealed that expression of a subset of differentiation genes (e.g., *T*, *Cdx2*, *Wnt8a*, and *Sp5*) was initially induced in Smad2/3 DKO day 2 EBs but failed to be maintained. These transcriptional changes were validated for selected genes by immunofluorescent staining ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Experiments analyzing single-KO EBs demonstrate that both Smad2/3 contribute to expression changes ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3C). When differentially expressed genes in Smad2/3 DKO day 3 EBs were assessed for their relative expression changes in Smad2/3 DKO EpiLCs and ESCs, we found that Smad2/3 is essential for correct gene expression patterns during differentiation at early stages as cells enter the primed state ([Figure S3](#mmc1){ref-type="supplementary-material"}D).Figure 3Smad2/3 Governs Embryonic Cell Fate Specification(A) Heatmap showing the log2 fold change (log2FC) in expression of the top 20 genes upregulated in day 3 WT EBs relative to WT ESCs (left) in comparison with their expression changes in Smad2/3 DKO (right). See also [Table S1](#mmc2){ref-type="supplementary-material"}.(B) Anti-AP2γ and Oct4 immunofluorescence staining of WT and Smad2/3 DKO day 2 and 4 PGCLCs.(C) WT and Smad2/3 DKO NPCs at day 7 stained with anti-Tuj1 and counterstained with DAPI.(D) Bright-field images of control WT or Smad2/3 DKO NPCs grown in the absence or presence of BMP4 (5 ng/mL) at days 3, 5, and 7.(E) WT and Smad2/3 DKO NPCs grown in the absence or presence of BMP4 (5 ng/mL) stained with anti-Sox1 and Ap2γ and counterstained with DAPI at day 5.

Primordial germ cells (PGCs) are specified in the early epiblast in response to Bmp signaling from the extra-embryonic ectoderm. To test whether PGC specification is affected by loss of Smad2/3, we exploited PGC-like cell (PGCLC) differentiation protocols ([@bib21]). AP2γ/Oct4 co-expression identifies PGCs in the early embryo. In WT cultures, Oct4/AP2γ double-positive cells were readily apparent at day 2 and abundant numbers were present at day 4, but by contrast, day 2 and 4 Smad2/3 DKO cultures contained predominantly Oct4 and AP2γ single-positive cells ([Figure 3](#fig3){ref-type="fig"}B), allowing us to conclude that their ability to acquire PGC-like fates is also compromised.

Smad2/3 Governs the Balance of Nodal/Bmp Signaling during Ectoderm Specification {#sec2.7}
--------------------------------------------------------------------------------

To evaluate whether ectodermal cell fate decisions are also Smad2/3 dependent, we exploited culture protocols that promote neuroectodermal precursor cell (NPC) formation. Tuj1+ staining identified a subpopulation of *bona fide* elongated neural cells in day 7 Smad2/3 DKO cultures ([Figure 3](#fig3){ref-type="fig"}C). However, as for BMP4-treated WT NPCs ([@bib35]), from day 3 onward, most cells displayed a flattened epithelial, surface-ectoderm-like morphology ([Figure 3](#fig3){ref-type="fig"}D). At day 5, a high proportion of WT cells expresses the early neural marker Sox1. BMP4 treatment normally represses Sox1 expression in WT cultures ([Figures 3](#fig3){ref-type="fig"}E and [S3](#mmc1){ref-type="supplementary-material"}E). In Smad2/3 DKO NPCs, the proportion of Sox1+ cells is markedly reduced, but not eliminated. Similarly, expression of the neural marker *Six3* was absent from BMP4-treated NPCs and significantly reduced in Smad2/3 DKO NPCs ([Figure S3](#mmc1){ref-type="supplementary-material"}E). Moreover, Smad2/3 DKO NPCs exhibited ectopic expression of AP2γ and the epithelial marker *Krt18*, normally present only in BMP4-treated WT cultures ([Figures 3](#fig3){ref-type="fig"}E and [S3](#mmc1){ref-type="supplementary-material"}E). Thus, neural fate appears to be induced in a subpopulation of Smad2/3 DKO cells. However, terminal differentiation of neuroectodermal cells is compromised, possibly due to increased Bmp signaling. Thus, as reported for Alk4/5/7 inhibitor-treated ectoderm explants ([@bib33]), here we found that combinatorial Smad2/3 activities are required for fine-tuning the balance of neural versus epidermal cell fates.

Ectopic Activation of Extra-Embryonic Gene Expression in Smad2/3-Deficient EBs {#sec2.8}
------------------------------------------------------------------------------

Expression of Bmp target genes (*Id1*--*Id4*) was upregulated in Smad2/3 DKO compared to WT ESCs, EpiLCs, and day 3 EBs, consistent with increased levels of Bmp signaling activities ([Figure 4](#fig4){ref-type="fig"}A). To examine this possibility, we differentiated Smad2/3 DKO EBs in the presence and absence of the Bmp type 1 receptor inhibitor LDN-193189. In contrast to WT EBs, in which Bmp receptor inhibition markedly reduced p-S1/5/8 levels, we found that Smad2/3 DKO EBs are refractory to LDN-193189 treatment, with levels of p-S1/5/8 and Id1 remaining unchanged ([Figure 4](#fig4){ref-type="fig"}B). Next, we evaluated possibly elevated Bmp signaling in embryonic day 5.5 (E5.5) double-mutant embryos. In WT embryos p-S1/5/8 staining is restricted to the proximal VE, while in mutant embryos ectopic nuclear p-S1/5/8 staining is present throughout the VE ([Figure 4](#fig4){ref-type="fig"}C). Consistent with this, in double-mutant embryos VE specification is disrupted, as seen by loss of both Eomes and Otx2 expression ([Figure 4](#fig4){ref-type="fig"}D).Figure 4Enhanced Bmp Signaling Caused by the Absence of Smad2/3 Disturbs Embryonic Patterning(A) Heatmap showing the log2FC in expression of selected Bmp target genes and those involved in DNA methylation for Smad2/3 DKO ESCs, EpiLCs, and day 3 EBs compared to WT controls (n = 3 or 4).(B) Western blot analysis of WT and Smad2/3 DKO day 3 EBs treated with DMSO or LDN-193189 (250 nM, 24 hr from day 2 to day 3) or untreated. Blots were probed with the indicated antibodies.(C and D) Anti-p-Smad1/5/8 and Oct4 (C) or Eomes and Otx2 (D) immunofluorescence staining of E5.5 WT or Smad2/3 DKO mouse embryos.(E) Heatmap showing the log2FC in expression of the top 20 upregulated genes (p \< 0.05, fold change \> 1.5) in Smad2/3 DKO day 3 EBs compared to WT day 3 EBs and their expression changes in Smad2 KO and Smad3 KO day 3 EBs (n = 4, averaged). See also [Table S1](#mmc2){ref-type="supplementary-material"}.

Bmp signaling has been shown to activate extra-embryonic gene expression ([@bib22]). Similarly, in Smad2/3 DKO day 3 EBs, a subset of trophectoderm-derived, extra-embryonic tissue-expressed genes (e.g., *Plac1*, *Rhox6*, *Rhox9*, and *Ascl2*) and VE genes (e.g., *H19*) shows strongly upregulated expression ([Figure 4](#fig4){ref-type="fig"}E). However, expression of other essential extra-embryonic genes (e.g., *Elf5*) was unaffected. Thus, we conclude that Smad2/3-deficient cells are not simply defaulting to defined extra-embryonic fates.

Embryonic and extra-embryonic tissues in the early post-implantation mouse embryo show distinct patterns of DNA methylation ([@bib57]). In addition, in the epiblast, DNA methylation gradually increases, coincident with the exit from naive pluripotency ([@bib3], [@bib29]). Reduced DNA methylation has been shown to cause disturbances, affecting the maintenance of embryonic and/or extra-embryonic cell identity and ESC differentiation ([@bib28], [@bib45], [@bib52]). Reduced Bmp signaling in Smad1/5 DKO ESCs results in increased *Dnmt3b* levels, enhanced DNA methylation, and more efficient embryonic differentiation ([@bib19]). Consistent with enhanced Bmp signaling, we found that Smad2/3 DKO day 3 EBs display decreased *Dnmt3b* expression and increased expression of genes associated with DNA demethylation (*Tet2* and *Gadd45b*) ([Figure 4](#fig4){ref-type="fig"}A). Extra-embryonically expressed imprinted genes (e.g., *Rhox5*, *H19*, *Igf2*, *Ascl2*, and *Peg10*), whose differential expression is controlled by DNA methylation, were also upregulated ([Table S1](#mmc2){ref-type="supplementary-material"}). It is tempting to speculate that ectopic extra-embryonic gene expression in Smad2/3-deficient EBs reflects enhanced Bmp signaling, together with changes affecting the patterns of DNA methylation.

Discussion {#sec3}
==========

We reported many years ago that double Smad2/3 homozygous mutant embryos abruptly arrest at early post-implantation stages ([@bib14]). However, it has proved difficult to characterize the underlying molecular defects responsible for this early lethality. Here we generated double Smad2/3 homozygous null ESCs and investigated their differentiation capabilities. Our genome-wide transcriptional profiling experiments demonstrate that Smad2/3 activities in early epiblast cells are required to promote the transition from naive pluripotency to lineage priming and the onset of cell fate allocation.

Our ATAC-seq analysis of Smad2/3 DKO EpiLCs revealed changes in chromatin accessibility at distal regulatory elements occupied by the pioneer transcription factor Oct4 and its interaction partner Otx2 ([@bib7], [@bib30]). These changes were closely associated with expression changes at nearby genes. Oct4 interactions with Smad2/3 were previously described in naive and primed cells ([@bib43], [@bib59]). It has been proposed that Smad2/3 facilitates accessibility at Oct4-dependent enhancer sites through interactions with chromatin modifiers and remodelers ([@bib18], [@bib51]). The present experiments support the idea that Smad2/3/Oct4/Otx2 transcription complexes are required to mediate cellular transitions from naive to primed and primed to differentiated states. It will be interesting to learn more about associations with additional cofactors having an impact on chromatin structure and transcriptional output at specific target loci.

Early epiblast cells normally undergo lineage priming in the context of tightly balanced reciprocal Nodal/Smad2 and Bmp/Smad1 signaling cues between the embryonic and the extra-embryonic tissues ([@bib4], [@bib64]). The present experiments demonstrate that Smad2/3 inactivation results in upregulated Bmp target and extra-embryonic gene expression. Similarly, in Smad2/3 double-mutant embryos, we find ectopic Bmp signaling throughout the distal VE. Studies also suggest that Bmp signaling promotes DNA hypo-methylation in ESCs ([@bib19]). It is tempting to speculate that Smad2/3 activities normally antagonize Bmp signaling and promote DNA methylation selectively in the early epiblast to maintain its developmental potential and prevent contributions to the extra-embryonic cell lineages.

Smad2/3 DKO embryos are more severely disturbed and die earlier in comparison with Nodal KO embryos ([@bib6], [@bib14]). Similarly, Smad2/3 DKO ESCs display more striking differentiation defects compared with Nodal KO ESCs. For example, Nodal KO embryos and ESCs induced to differentiate have been shown to prematurely activate neural gene expression ([@bib9], [@bib42]). In contrast, we found that Smad2/3 DKO ESCs induced to differentiate display reduced neural and enhanced surface ectoderm-like and extra-embryonic gene expression. The simplest explanation is that in the absence of Nodal, closely related Smad2/3-dependent TGF-β family members like Gdf1 and Gdf3 partially compensate ([@bib1]). Consistent with this possibility, Nodal-deficient blastocysts have the ability to activate the Smad2/3-dependent Nodal anterior streak enhancer ([@bib20]). Moreover, unlike Smad2/3 DKO ESCs, Nodal KO ESCs efficiently contribute to embryonic cell lineages ([@bib11]). Widespread tissue defects observed in Smad2/3 DKO embryos are also considerably more severe compared with those reported for mutant embryos lacking *Fgf5*, *Oct6*, or *Otx2* ([@bib2], [@bib5], [@bib24]). Thus, it appears that the profound developmental block in Smad2/3 DKO embryos reflects not only defective lineage priming and embryonic cell fate allocation but also additional disturbances caused by de-repressed Bmp target gene and ectopic extra-embryonic gene expression. Overall, our experiments demonstrate that combinatorial Smad2/3 functional activities collaboratively maintain distinct embryonic and/or extra-embryonic cell identities and strictly divergent lineage-specific transcriptional programs in the early mouse embryo.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rabbit polyclonal anti-mouse NanogAbcamCat\#ab80892; RRID: [AB_2150114](nif-antibody:AB_2150114){#intref0010} Lot: GR40243-12Goat polyclonal anti-mouse Oct4Santa CruzCat\#sc-8628; RRID: [AB_653551](nif-antibody:AB_653551){#intref0015}, Lot: F1815Mouse monoclonal anti-mouse Klf4Santa CruzCat\#sc-393462, Lot: iO116Rabbit polyclonal anti-human Ap2γSanta CruzCat\#sc-8977; RRID: [AB_2286995](nif-antibody:AB_2286995){#intref0020}, Lot: G1112Goat polyclonal anti-human Brachyury (N-19)Santa CruzCat\#sc-17743; RRID: [AB_634980](nif-antibody:AB_634980){#intref0025}, Lot: A1614Rat monoclonal anti-mouse E-CadherinSigma-AldrichCat\#U3254; RRID: [AB_477600](nif-antibody:AB_477600){#intref0030}, Lot: 085K4798Goat polyclonal anti-human Gata6R&D SystemsCat\#AF1700; RRID: [AB_2108901](nif-antibody:AB_2108901){#intref0035}, Lot: KWT-417101Mouse monoclonal anti-human Cdx2BioGenexCat\#MU392A-UC; RRID: [AB_2650531](nif-antibody:AB_2650531){#intref0040}, Lot: MU392A0713Rabbit polyclonal anti-mouse EomesAbcamCat\#ab23345; RRID: [AB_778267](nif-antibody:AB_778267){#intref0045}, Lot:GR306193-1Rabbit monoclonal anti-human Smad1/5/8 (embryo)Cell Signaling TechnologyCat\#13820; RRID: [AB_2493181](nif-antibody:AB_2493181){#intref0050}, Lot: D5810Rabbit polyclonal anti-human Smad1/5/8 (Western blot)Merck-MilliporeCat\#AB3848; RRID: [AB_628261](nif-antibody:AB_628261){#intref0055}, Lot: JBC17774748Mouse monoclonal anti-human Smad1Santa CruzCat\#sc-7965; RRID: [AB_628261](nif-antibody:AB_628261){#intref0060}, Lot: A072Rabbit polyclonal anti-mouse Id1Santa CruzCat\#sc-488; RRID: [AB_631701](nif-antibody:AB_631701){#intref0065}, Lot: B082Mouse monoclonal anti-mouse p-Smad2BD TransductionCat\#610843; RRID:[AB_398162](nif-antibody:AB_398162){#intref0070}, Lot: 3288899Rabbit monoclonal anti-human Smad3AbcamCat\#ab40854; RRID: [AB_777979](nif-antibody:AB_777979){#intref0075}, Lot: GR16548-6Rabbit polyclonal anti-human TubulinSanta CruzCat\#sc-9104; RRID: [AB_2241191](nif-antibody:AB_2241191){#intref0080}, Lot:I1009Mouse polyclonal anti-rat Tuj1Bio LegendCat\#801201; RRID: [AB_2313773](nif-antibody:AB_2313773){#intref0085}, Lot: B209227Goat polyclonal anti-human Sox1R&D SystemsCat\#AF3369; RRID: [AB_2239879](nif-antibody:AB_2239879){#intref0090}, Lot:XUV0417031Goat polyclonal anti-human Otx2R&D SystemsCat\#AF1979; RRID: [AB_2157172](nif-antibody:AB_2157172){#intref0095}, Lot: KNO0615111Goat polyclonal anti-human Oct6Santa CruzCat\#sc-11661; RRID: [AB_2268536](nif-antibody:AB_2268536){#intref0100}Donkey anti-goat Alexa 594Molecular ProbesCat\#A11058; RRID: [AB_142540](nif-antibody:AB_142540){#intref0105}Donkey anti-goat Alexa 488Molecular ProbesCat\#A11055; RRID: [AB_142672](nif-antibody:AB_142672){#intref0110}Donkey anti-mouse Alexa 488Molecular ProbesCat\#A21202; RRID: [AB_141607](nif-antibody:AB_141607){#intref0115}Donkey anti-rabbit Alexa 594Thermo Fisher ScientificCat\#A21207; RRID: [AB_141637](nif-antibody:AB_141637){#intref0120}Donkey anti-goat Alexa 594Molecular ProbesCat\#A11058; RRID: [AB_142540](nif-antibody:AB_142540){#intref0125}Donkey anti-rabbit Alexa 488Molecular ProbesCat\#A21206; RRID: [AB_141708](nif-antibody:AB_141708){#intref0130}Donkey anti-rat 594Molecular ProbesCat\#A21209; RRID: [AB_2535795](nif-antibody:AB_2535795){#intref0135}Donkey anti-rabbit HRPGE HealthcareCat\#NA934; RRID: [AB_772206](nif-antibody:AB_772206){#intref0140}Sheep anti-mouse HRPGE HealthcareCat\#NA931; RRID: [AB_772212](nif-antibody:AB_772212){#intref0145}**Bacterial and Virus Strains**One Shot Stbl3 Chemically Competent *E. coli*InvitrogenCat\#C737303**Chemicals, Peptides, and Recombinant Proteins**Recombinant human/murine/rat Activin APeprotechCat\#120-14E, Lot: 1115478-1Recombinant human bFGFInvitrogenCat\#13256-029, Lot: 1711319ALDN-193189 (small molecule inhibitor)StemgentCat\#04-0074, Lot: 3061Recombinant human BMP4R&D SystemsCat\#314-BP, Lot: BEM11816121Recombinant mouse SCFR&D SystemsCat\#455-MC, Lot: CW1715062Recombinant human Bmp8R&D SystemsCat\#1073-BP, Lot: EXU1116031Recombinant mouse EGFR&D SystemsCat\#2028-EG, Lot: MKG1016021Human plasma fibronectin purified proteinMilliporeCat\#FC010CHIR99021Synthesized by the MRC Protein Phosphorylation Unit, Division of Signal Transduction Therapy at the University of Dundee, UKN/APD0325091Synthesized by the MRC Protein Phosphorylation Unit, Division of Signal Transduction Therapy at the University of Dundee, UKN/ARecombinant LIF (ESGRO)MilliporeCat\#ESG1107, Lot: 2710245**Critical Commercial Assays**Alkaline Phosphatase Detection KitMilliporeCat\#SCR004Nextera DNA Library Preparation KitIlluminaCat\#FC-121-1030**Deposited Data**RNA-seq on Smad2/3 DKO and control epiblast-like cellsN/AGEO: [GSE110163](ncbi-geo:GSE110163){#intref0150}, [Table S2](#mmc3){ref-type="supplementary-material"}, Series GSE110164ATAC-seq on Smad2/3 DKO and control epiblast-like cells (including Tn5 control)N/AGEO: [GSE110162](ncbi-geo:GSE110162){#intref0155}, [Table S3](#mmc4){ref-type="supplementary-material"}, Series GSE110164Illumina MouseWG-6 v2.0 Expression BeadChip microarray on Smad2/3 DKO, Smad2 KO, Smad3 KO and WT mouse ESCs, d2 and d3 EBsN/AGEO: [GSE110058](ncbi-geo:GSE110058){#intref0160}, [Table S1](#mmc2){ref-type="supplementary-material"}, Series GSE110164**Experimental Models: Cell Lines**WT CCE 129/Sv//Ev embryonic stem cells([@bib49])N/A*Smad2^t^*^*m1Rob/tm1Rob*^ 129/Sv//Ev embryonic stem cells([@bib60])N/A*Smad3*^*tm1Xfw/tm1Xfw*^ 129/Sv ^∗^ C57BL/6 embryonic stem cellsThis studyN/A*Smad3*^*CRISPR/CRISPR*^ 129/Sv//Ev embryonic stem cellsThis studyN/A*Smad2*^*tm1Rob/tm1Rob*^*;Smad3*^*CRISPR/CRISPR*^ 129/Sv//Ev embryonic stem cellsThis studyN/ANIH 3T3 cellsATCCRRID: CVCL_0594**Experimental Models: Organisms/Strains**Mouse: *Smad3*^*tm1Xfw*^*/+*: C57BL/6Obtained from ([@bib12])RRID: MGI:2182651Mouse: Smad2^tm1Rob^/+: C57BL/6([@bib62])MGI:[1857691](mgi:1857691){#intref0165}**Oligonucleotides**Smad3 CRISPR_5′ nick 1 forward CACCGCCCACG\
TGGGCCACCGGGTAGGGThis studyN/ASmad3 CRISPR_5′ nick 1 reverse AAACTACCCGGT\
GGCCCACGTGGGCThis studyN/ASmad3 CRISPR_5′ nick 2 forward CACCGCGCTG\
GCGGCGCTGGGCGGGGThis studyN/ASmad3 CRISPR_5′ nick 2 reverse AAACCGCCCA\
GCGCCGCCAAGCGCThis studyN/ASmad3 CRISPR_3′ nick 1 forward CACCGTGTCCC\
GCCCCACTCGAAGCGCThis studyN/ASmad3 CRISPR_3′ nick 1 reverse AAACCCGCTT\
CGAGTGGGGCGGGACACThis studyN/ASmad3 CRISPR_3′ nick 2 forward CACCGTCAGTA\
CATTCTGTCAGATCTGGThis studyN/ASmad3 CRISPR_3′ nick 2 reverse AAACCCAGAT\
CTGACAGAATGTACTGACThis studyN/ACRISPR_U6 sequencing primer forward GACTATCAT\
ATGCTTACCGTThis studyN/APrimers for qRT-PCR and OneStep RT-PCR analysis as well as mouse genotyping and Southern blot probe, see [Table S4](#mmc1){ref-type="supplementary-material"}This studyN/A**Recombinant DNA**pSpCas9n(BB)-2A-GFP (PX461)([@bib47])Addgene Plamid \#18140**Software and Algorithms**CRISPR design tool([@bib26])<http://crispr.mit.edu>Bowtie2 aligner([@bib31])<http://bowtie-bio.sourceforge.net/bowtie2/index.shtml>STAR aligner([@bib13])<https://github.com/alexdobin/STAR>Samtools([@bib32])<http://samtools.sourceforge.net/>Danpos2([@bib10])<https://sites.google.com/site/danposdoc/>MACS2([@bib66])<https://github.com/taoliu/MACS>bedtools([@bib46])<http://bedtools.readthedocs.io/en/latest/#>UCSC Genome Browser<https://genome.ucsc.edu/>DiffBind R package([@bib50])<https://bioconductor.org/packages/release/bioc/html/DiffBind.html>DESeq2 R package([@bib34])<http://bioconductor.org/packages/release/bioc/html/DESeq2.html>HOMER([@bib25])<http://homer.ucsd.edu/homer/index.html>JavaTreeView([@bib53])<http://jtreeview.sourceforge.net/>Analysis of Motif Enrichment Feature in the MEME suite([@bib38])<http://meme-suite.org/doc/ame.html?man_type=web>GREAT([@bib37])<http://bejerano.stanford.edu/great/public/html/>Arrayanalysis([@bib16])<http://www.arrayanalysis.org/>BioVenn([@bib27])<http://www.biovenn.nl/>Fiji([@bib54])<https://imagej.net/Fiji>**Other***Mus musculus* rRNA genomic sequenceGenBankBK000964.3mm10 genomeUCSC Genome Browser<http://hgdownload.cse.ucsc.edu/goldenPath/mm10/bigZips/>Sequencing data from Oct4, Otx2, p300, H3K4me1 and H3K27ac ChIP-seq in EpiLCs and RNA-seq in mouse ESCs and EpiLCs([@bib7])GSE56138Sequencing data from Smad2/3 ChIP-seq in mouse ESCs and embryoid bodies treated with Activin A or SB-431242([@bib63])GSE70486Sequencing data from ATAC-seq in mouse ESCs and *in vitro* differentiated definitive endoderm([@bib55])GSE94250Sequencing data from Smad1 ChIP-seq in mouse ESCs treated with BMP4([@bib41])GSE70581

Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Elizabeth Robertson (<elizabeth.robertson@path.ox.ac.uk>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Animal care and use {#sec4.3.1}

E5.5 Smad2/3 DKO embryos were obtained from intercrosses of *Smad3*^*tm1Xfw*/+^*;Smad2*^*tm1Rob*/+^ ([@bib62], [@bib12]) animals. Blastocysts for ESC derivation and thymus tissue for protein lysates were obtained from the *Smad3*^*tm1Xfw*^ C57BL/6 mouse strain ([@bib12]). PCR genotyping primers are listed in [Table S4](#mmc1){ref-type="supplementary-material"}. All animal experiments were performed in accordance with Home Office (UK) regulations and approved by the University of Oxford Local Ethical Committee.

### ESC culture {#sec4.3.2}

All ESC lines used were XY and grown in feeder-free conditions on 0.1% gelatin-coated dishes at 6% CO~2~ at 37°C. ESCs were cultured in DMEM (GIBCO, Cat\#11960-085) supplemented with 15% FBS (GIBCO Cat\#10500-062, Lot: 07Q3446K), 1% PEN/STREP, 1% glutamine, 1% NEAA, 1mM sodium pyruvate, 100 μM β-mercaptoethanol and 1000 U/ml LIF (SL). Alternatively, ESCs were cultured in serum-free media containing N2B27 (NDiff®227, Cat\#Y40002) supplemented with 1 μM PD0325091 and 3 μM CHIR99021 and 1000 U/ml LIF (2iL).

Method Details {#sec4.4}
--------------

### Generation of knockout lines {#sec4.4.1}

#### Smad3 KO and Smad2/3 DKO ESC lines {#sec4.4.1.1}

Two sets of four sgRNAs flanking exon 1 of murine *Smad3* were designed using the Zhang lab CRISPR design tool ([@bib26]) taking care to avoid T-rich 3′ ends and to keep off-sets between nickase-sgRNAs \< 10 bp. The PAM sequence was removed and *BbsI* sites engineered at the ends. After cloning into pSpCas9n(BB)-2A-GFP (PX461) ([@bib47]) constructs were transfected into Stbl3 cells. Efficiency of sgRNA plasmids was confirmed by high resolution melt analysis. A maximum of 5 μg pooled isolated non-linearized plasmid DNAs (QIAGEN Maxi Prep kit, Cat\#12663) was transfected into 1 × 10^6^ ESCs (either 129/Sv//Ev CCE WT ([@bib49]) or *Smad2*^*tm1Rob/tm1Rob*^ ([@bib60])) using the Neon® transfection system (Thermo Fisher Scientific, Cat\#MPK5000) followed by low-density plating. Deletion of exon 1 was screened for by Southern blotting using a *XbaI* digest and a probe 3′ to the deletion (for sequences see [Table S4](#mmc1){ref-type="supplementary-material"}). Loss of Smad3 protein was confirmed by western blotting using specific antibodies (see [Key Resources Table](#sec4.1){ref-type="sec"}).

#### Conventional Smad3^−/−^ control lines {#sec4.4.1.2}

To generate *Smad3*^*−/−*^ ESCs, blastocysts were obtained from *Smad3*^*tm1Xfw*/+^ females mated to *Smad3*^*tm1Xfw*/+^ males. ESC lines were isolated in 2iL as previously described ([@bib65]). Homozygous lines were identified by PCR using the genotyping primers listed in [Table S4](#mmc1){ref-type="supplementary-material"}.

### EpiLC induction {#sec4.4.2}

EpiLCs were induced from ESCs (2iL) as previously described ([@bib23]). In brief, 2.33 × 10^5^ cells were washed and resuspended in N2B27 medium (Takara, Cat\#Y40002) supplemented with 12ng/ml Fgf2, 20ng/ml Activin A and 1% KSR (GIBCO, Cat\#10828, Lot:1508151) and grown on fibronectin-coated (5 μg/cm^2^) 6cm dishes. Medium was exchanged daily and cells grown for 48h to form EpiLCs.

### PGCLC induction {#sec4.4.3}

PGCLCs were induced from d2 EpiLCs as described previously ([@bib21]). In brief, 2000 cells were washed and plated into lipidure-coated U-bottom shaped 96-well plates in serum-free medium (GK15; GMEM (Invitrogen) with 15% KSR, 0.1 mM NEAA, 1 mM sodium pyruvate, 0.1 mM 2-mercaptoethanol, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 2 mM L-glutamine) in the presence of the cytokines BMP4 (500 ng/ml; R&D Systems), LIF (1000 u/ml; Invitrogen), SCF (100 ng/ml; R&D Systems), BMP8b (500 ng/ml; R&D Systems), and EGF (50 ng/ml; R&D Systems).

### EB differentiation {#sec4.4.4}

ESCs (SL) were trypsinized, resuspended in serum-containing medium without LIF (EB medium), pelleted, washed in PBS (w/o MgCl~2~) and counted. A single-cell solution of 1 × 10^4^ cells/ml in EB medium was pipetted into 10 μL drops onto square 12cm plates and inverted to generate hanging drops. After 48 h the resultant EBs were harvested and either collected (d2 EB) or kept in suspension for further 24h (d3 EB) or 48h (d4 EB). For LDN-193189 treatment, d2 EBs were harvested as above after 48h and plated in EB medium containing LDN-193189 (250nM; Stemgent) or equal amounts of DMSO carrier for 24h. As controls, serum-starved NIH 3T3 cells were treated with Bmp4 (50ng/ml) for 30min (or left untreated).

### NPC induction {#sec4.4.5}

ESCs (SL) were trypsinized when 70%--80% confluent and washed twice in N2B27. 1 × 10^4^ cells/cm^2^ were plated in N2B27 medium on fibronectin-coated (5 μg/cm^2^) dishes. Medium was changed on the second day of differentiation and then daily.

### ATAC-seq {#sec4.4.6}

Tagmentation and indexing of single cell suspensions (75,000 cells in technical duplicates) of three independent differentiation of Smad2/3 DKO or WT EpiLCs was performed as previously described ([@bib8]). To control for sequence bias of the Tn5 transposase, 100ng genomic DNA of WT EpiLCs was also tagmented and indexed. Samples were sequenced using a 75-cycle paired end Nextera kit with custom Nextera index primers Ad2.1-2.13 taken from [Table S1](#mmc2){ref-type="supplementary-material"} in [@bib8] on the Illumina HiSeq4000 platform.

### Microarray profiling {#sec4.4.7}

d2 and d3 EBs were harvested, washed and total RNA isolated (QIAGEN RNAeasy micro kit, Cat\# 74004). Four independent clones were used per genotype. Undifferentiated cells were collected prior to EB set-up. Biotinylated cRNA (1.5 μg RNA per sample) was randomly hybridized to Illumina MouseWG-6 v2.0 Expression BeadChip microarrays.

### RNA-seq {#sec4.4.8}

RNA was isolated from ∼1.5 x10^6^ Smad2/3 DKO and WT EpiLCs from three independent EpiLC differentiations per genotype, using samples taken from the same cells used for ATAC-seq (QIAGEN RNeasy mini kit, Cat\#74104). Total RNA was normalized to 800ng per sample, depleted of cytoplasmic and mitochondrial ribosomal RNA sequences (Ribo-Zero Gold rRNA Removal Kit (H/M/R), Cat: \#MRZG12324) and used for library preparation using the Illumina TruSeq Stranded Total RNA Library Prep (H/M/R) (Cat: \#20020597), followed by sequencing (75-cycle paired end) on the Illumina HiSeq4000 platform.

### RT-PCR {#sec4.4.9}

1 μg RNA was reverse transcribed to cDNA using Superscript III First Strand Synthesis System (Life Technologies, Cat\#18080-051) and diluted to 160 μL final volume in H~2~O. 2 μL were used per qRT-PCR reaction in duplicate using SYBR-green kit (QIAGEN, Cat\#204143). Relative gene expression was normalized to *Gapdh* expression and calculated as 2^ΔΔ^Ct. OneStep RT-PCR analysis was performed on 50ng RNA using OneStep RT-PCR kit (QIAGEN, Cat\#210210) following the manufacturers protocols. Samples were run on 2% agarose/1xTAE gels. qRT-PCR and OneStep RT-PCR primer sequences are listed in [Table S4](#mmc1){ref-type="supplementary-material"}.

### Immunofluorescence {#sec4.4.10}

ESCs or EpiLCs grown in 8-well chamber slides were washed twice in PBS (with MgCl~2~) and fixed in 4% PFA (10min at RT). After three further washes, cells were permeabilized in PBS plus 0.2% Triton X-100, followed by two washes in PBS plus 0.05% Tween-20 (PBST) then blocked (10% donkey serum and 1% BSA in PBST for 1h at RT) and incubated with primary antibodies in blocking solution (see above) (o/n at 4°C). Following two washes in PBST, cells were incubated with fluorescence-labeled secondary antibodies in blocking solution for 1h at RT followed by two washes in PBST containing 2 μg/ml DAPI prior to mounting in Vectashield with DAPI (H-1200) and imaging on a Leica epifluorescence microscope. d2 and d3 EBs, d2 and d4 PGCLCs and E5.5 mouse embryos were harvested, washed in PBS (with MgCl~2~), fixed in 1% PFA o/n at 4°C. After three washes in PBS containing 0.1% Triton X-100 (PBSTr), samples were permeabilized in PBS containing 0.5% Triton X-100 followed by three washes in PBSTr then blocked (5% donkey serum and 0.2% BSA in PBSTr for 1h at RT) and incubated with primary antibodies in blocking solution (o/n 4°C). Following four washes in PBSTr samples were incubated with fluorescence-labeled secondary antibodies in blocking solution (2h, RT) followed by three washes in PBSTr, one wash in PBSTr containing 2 μg/ml DAPI and three washes in PBSTr prior to mounting in Vectashield with DAPI (H-1200). Samples were imaged the following day on an Olympus Fluoview FV1000 confocal microscope. Antibodies are listed in the [Key Resources Table](#sec4.1){ref-type="sec"}.

### Colony forming assay {#sec4.4.11}

675 single ESCs (SL) of three independent clones per genotype were seeded on gelatin coated 6cm dishes and fed daily. On day 7 colonies were washed with PBS, fixed with 70% ethanol (10min, room temperature) stained with Giemsa stain (GIBCO) for 15min at RT, washed extensively with tap water and air-dried. Colony area surface was measured at day 5 of colony formation using Fiji ([@bib54]).

### Alkaline phosphatase staining {#sec4.4.12}

600 single ESCs (SL) from three independent clones per genotype were seeded. The following day, medium was exchanged to medium without or with LIF and replaced daily. On d5 cells were washed in PBS, fixed in 4% PFA (1min at RT), washed in TBST, stained with alkaline phosphatase staining solution (Millipore, Cat\#SCR004) for 15 min at RT, washed in TBST and imaged. Differentiated, mixed and undifferentiated colonies were scored and counted.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

### RT-PCR {#sec4.5.1}

Statistical significance between Smad2/3 DKO and WT samples was determined using the R function wilcox.test with default parameters. Significance levels are denoted by ^∗^ for p \< 0.05 and ^∗∗^ for p \< 0.01.

### Microarray analysis {#sec4.5.2}

Bead-Station data were extracted using the Gene Expression Analysis Module V1.6.0 of GenomeStudio V2009.2 (Illumina) and imported into an R-based Illumina pre-processing module ([@bib16]). Hierarchical clustering identified three outlier samples in ESCs that were excluded from subsequent analysis. Differential probe expression was determined using an R-based statistical analysis module ([@bib16]) with raw *p* values compared to averaged WT signal at the same time-point. Unique ILMN_GENE gene identifiers of probes with significantly different expression (p \< 0.05 and fold change \> 1.5) were identified and were analyzed using Venn diagram overlaps ([@bib27]). For WT top expressed genes, d3 EB datasets were compared to averaged ESC datasets. Heatmaps of log2FC values for individual clones were made using Java TreeView ([@bib53]).

### ATAC-seq, ChIP-seq and RNA-seq analysis {#sec4.5.3}

Paired-end reads for ATAC-seq and ChIP-seq were aligned to the mouse mm10 genome using bowtie2 ([@bib31]) with the "--no-mixed" and "--no-discordant" options. Non-uniquely mapping reads and reads mapping to a custom "blacklist" of artificially high regions of the genome were discarded. For RNA-seq, reads were initially aligned using bowtie2 against the rRNA genomic sequence (GenBank: [BK000964.3](ncbi-n:BK000964.3){#intref0265}) to filter out rRNA fragments, prior to alignment against the mm10 genome using the STAR RNA-seq aligner with default parameters ([@bib13]) PCR duplicates were removed using Samtools ([@bib32]). Biological replicates were randomly downsampled to contain the same number of reads for each individual replicate, and merged to create a representative genome track using DANPOS2 ([@bib10]) for ATAC-seq samples and MACS2 ([@bib66]) for ChIP-seq and genomecov from bedtools ([@bib46]) for RNA-seq. Genome coverage tracks were visualized using the UCSC Genome Browser.

ATAC hypersensitive sites in both WT and SMAD2/3 null EpiLCs were identified using the DANPOS2 dpeak function with biological triplicates and a Tn5 genomic DNA control. Significant changes in ATAC-seq datasets were identified using the DiffBind package ([@bib58]). For RNA-seq, the mm10 refGene gene bodies were annotated with biological replicate read counts and gene expression changes were identified with DESeq2 ([@bib34]). For both DiffBind and DESeq2, a FDR \< 0.05 and a fold change \> 1.5 was deemed a significant change. To link differential gene expression with Smad2/3 ChIP-seq signal in ESCs and EBs ([@bib63]), we called Smad2/3 peaks using DANPOS2, annotated peaks with the closest RefSeq TSS using HOMER ([@bib25]) and excluded peaks \> 50kb away from RefSeq TSSs.

Changes in ATAC-seq were visualized using heatmaps produced using HOMER and Java TreeView. GREAT was used to identify the distance of peaks to known TSS ([@bib37]). To identify accessibility changes during the ESC to EpiLC transition, we used ATAC-seq data from [@bib55] with DiffBind as above. To compare differential chromatin accessibility with changes in nearby gene expression, we used HOMER to identify the transcriptional start sites (TSS) nearest to sites with differential chromatin accessibility and visualized the log2FC gene expression changes in RNA-seq data from Smad2/3 DKO EpiLCs in comparison to WT EpiLCs as a heatmap. Differentially accessible sites in Smad2/3 DKO EpiLCs were annotated with published p300, H3K27ac, H3K4me1, Smad2/3, Smad1, Oct4 and Otx2 ChIP-seq data ([@bib7], [@bib41], [@bib63]). Enrichment of transcription factor motifs in differentially accessible ATAC-seq peaks was performed using the Analysis of Motif Enrichment (AME) feature in the MEME suite ([@bib38]) with a background control of unaffected ATAC-seq peaks.

Data and Software Availability {#sec4.6}
------------------------------

The accession number for the data reported in this paper is GEO: [GSE110164](ncbi-geo:GSE110164){#intref0270} (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110164>).
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Document S1. Figures S1--S3 and Table S4Table S1. Related to Figures 1 and 3List of differentially expressed genes (fold change \> 1.5; p \< 0.05, ILMN_GENE) in Smad2 KO, Smad3 KO and Smad2/3 DKO ESC, d2 EBs and d3 EBs as determined by microarray profiling (Illumina MouseWG-6 v2.0 Expression BeadChip microarrays) in comparison to WT ESCs, d2 and d3 EBs.Table S2. Related to Figure 2List of differentially expressed genes (fold change \> 1.5; adjusted p \< 0.05 (Benjamini-Hochberg), mm10 gene symbols) in Smad2/3 DKO d2 EpiLCs as determined by RNA-seq. Overlap with Smad2/3 ChIP-seq peaks within 50kb of TSS in ESCs and d3 EBs (Wang et al., 2017) is indicated.Table S3. Related to Figure 2List of genomic loci and closest mm10 genes with significantly changed (fold change \> 1.5, FDR \< 0.05) chromatin accessibility in Smad2/3 DKO d2 EpiLCs in comparison to WT d2 EpiLCs as determined by ATAC-seq.Document S2. Article plus Supplemental Information
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